Oncolytics Biotech Inc.
ONCY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $8 | $3 | $4 | $5 |
| G&A Expenses | $6 | $3 | $3 | $3 |
| SG&A Expenses | $6 | $3 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $14 | $6 | $7 | $8 |
| Operating Income | -$14 | -$6 | -$7 | -$8 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | -$0 | $0 | $0 |
| Pre-Tax Income | -$15 | -$6 | -$7 | -$8 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$14 | -$6 | -$7 | -$8 |
| % Margin | – | – | – | – |
| EPS | -0.14 | -0.068 | -0.079 | -0.1 |
| % Growth | -106.8% | 14.3% | 21% | – |
| EPS Diluted | -0.14 | -0.068 | -0.079 | -0.1 |
| Weighted Avg Shares Out | 101 | 91 | 85 | 76 |
| Weighted Avg Shares Out Dil | 101 | 91 | 85 | 76 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$15 | -$6 | -$7 | -$8 |
| % Margin | – | – | – | – |